AstraZeneca and Revvity Enters into Licensing Agreement for Pin-point Editing Technology to Treat Cancer and Immune-mediated Diseases
Shots:
- Through this non-exclusive agreement, AstraZeneca will receive access to the gene editing technology, Pin-point to develop cell therapy
- The Pin-point system enables highly efficient and precise single multi-gene editing without affecting cell viability or functionality by using a modified Cas enzyme that only created one strand of the DNA
- By using the Pin-point system, Base editing has been demonstrated in T-cells and iPSCs showing the potential across different cell types and indications. It spans gene modulation and editing, cell analysis, immunoassays, and optimized AAV and lentiviral vector development and manufacturing to improve the specificity, efficacy, and safety of cell and gene therapies
Ref: Businesswire | Image: Astrazenneca
Related News:- AstraZeneca Reports P-III Trial (FLAURA2) Results of Tagrisso (osimertinib) for the Treatment of EGFR-Mutated Advanced Lung Cancer
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
